Olaparib in treatment of men with mCRPC and selected HRR gene mutations | THE "NEW" PROSTATE CANCER INFOLINK: According to a media release issued by AstraZeneca and Merck on Friday evening, olaparib (Lynparza) has shown “a statistically significant and clinically meaningful improvement in … ove…
No comments:
Post a Comment